| 查看: 1803 | 回复: 101 | |||
[交流]
【转自药渡网】Teva 报告了乐观哮喘临床3期评估结果
|
|||
|
Teva 对临床3期评估了对于哮喘患者干粉吸入器 (MDPIs)吸入Fluticasone Propionate /Salmeterol和多剂量Fluticasone Propionate 的实验效果，实验数据很好。研究表明通过使用干粉吸入器 (MDPI)，低剂量与安慰剂相比具有更大的效能，结果展示 Teva 扩大呼吸的研发能力和支持其核心，呼吸驱动MDPI平台的发展。最初的结果显示fluticasone propionate/salmeterol MDPI的不良事件可以和fluticasone propionate治疗和安慰剂媲美。 相关阅读： Teva Reports Positive Top-Line Results from Phase III Trials Evaluating Fluticasone Propionate/Salmeterol and Fluticasone Propionate Multidose Dry Powder Inhalers (MDPIs) in Patients with Asthma Studies demonstrate greater efficacy with lower doses delivered via multidose dry-powder inhaler (MDPI) compared to placebo Results showcase Teva’s expanding respiratory R&D capabilities and support advancement of core, breath-actuated MDPI platform Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced positive top-line results from three Phase III clinical studies designed to evaluate the efficacy and safety of fluticasone propionate/salmeterol, a combination inhaled corticosteroid (ICS) and long-acting beta agonist (LABA) delivered via a multidose dry powder inhaler (MDPI) and fluticasone propionate, an ICS monotherapy delivered via a MDPI in adolescent and adult patients with asthma. Top-line data showed that the studies met their primary endpoints. Importantly, the studies also showed similar overall safety profiles as compared to therapies in the corresponding drug classes. “These data support Teva’s commitment to further optimize the treatment of respiratory disease through the development of devices and therapies that help address the needs of patients and physicians,” said Tushar Shah, MD, Senior Vice President, Teva Global Respiratory Research and Development. “With this dual development program we have demonstrated clinically significant levels of effectiveness, by delivering combination and monotherapy at lower doses utilizing our core, breath-actuated, MDPI platform.” Fluticasone propionate/salmeterol MDPI demonstrated, in the double-blind studies, clinically relevant and greater benefit at all doses (50/12.5, 100/12.5, and 200/12.5 mcg BID nominal delivered doses) versus placebo and versus respective monotherapy (fluticasone propionate) in the improvement of lung function as measured by the change from baseline in trough Forced Expiratory Volume in one second (FEV1) at the 12-week trial period and standardized baseline-adjusted area under the effect curve FEV1 from time 0 to 12 hours post dose at Week 12. This initial set of results shows the adverse event profile of fluticasone propionate/salmeterol MDPI was comparable to fluticasone propionate monotherapy and placebo. Fluticasone propionate MDPI also demonstrated clinically relevant and greater benefit at all doses (50, 100, and 200 mcg BID nominal delivered doses) versus placebo in the improvement of lung function, in the double-blind studies. The initial set of results shows the adverse event profile of fluticasone propionate MDPI was comparable to placebo. The majority of adverse events were mild to moderate in severity. There were no drug-related deaths across any of the trials. Further analyses of additional efficacy and safety data are ongoing. Full results will be submitted for presentation at future scientific meetings and for publication in peer reviewed journals. “We have made significant progress in furthering our respiratory pipeline with a focus on a complete asthma management system utilizing our breath-actuated MDPI platform,” said Michael Hayden, M.D., Ph.D., President of Global R&D and Chief Scientific Officer at Teva. “We have successfully developed and launched products that utilize our breath-actuated MDPI platform in select markets around the world. These data support the broadening of our portfolio in using this technology to develop and deliver additional respiratory therapeutic options.” Regulatory submissions for both fluticasone propionate/salmeterol MDPI and fluticasone propionate MDPI in the U.S. are planned for 2016. |
回复此楼» 猜你喜欢
调剂求收留
已经有6人回复
-
272分材料子求调剂
已经有36人回复
-
275求调剂
已经有8人回复
-
一志愿211，化学学硕，310分，本科重点双非，求调剂
已经有20人回复
-
070300化学学硕311分求调剂
已经有19人回复
-
材料与化工调剂
已经有13人回复
-
材料与化工调剂
已经有33人回复
-
复试调剂
已经有7人回复
-
一志愿哈工大 085600 277 12材科基求调剂
已经有17人回复
-
还有化工二轮调剂的学校吗
已经有47人回复
» 抢金币啦！回帖就可以得到:
-
大连大学-六盘水师范学院联合培养研究生接收调剂
+2/288
-
江西师大化学工程学院调剂今晚0点开放！ 缺额100个，速冲！
+1/87
-
中国水产科学研究院黄海水产研究所张旭志课题组招聘 可穿戴传感器研究 科研助理
+1/83
-
河南农业大学理学院仿生应用化学创新团队招收硕士调剂生
+1/56
-
2026年宁德师范学院新能源与材料学院硕士研究生调剂公告（第三批）
+2/44
-
大连工业大学纺织科学与工程接收硕士调剂
+1/40
-
武汉工程大学化学与环境工程学院2026年硕士研究生调剂公告
+1/13
-
浙江农林大学 林业与生物技术学院 生物学(生物化学与分子生物学) 第二轮调剂生招生
+1/13
-
重庆工商大学 教育部研究中心招收化工/环境/材料/石油/化机方向2026年调剂研究生
+1/12
-
湖南师范大学药物分析学2026年硕士研究生调剂
+1/11
-
太原科技大学光学工程学科接受调剂
+1/11
-
湖南理工大学调剂系统已开。 化学、化工、材料化工 调剂指标充足，录取率高，欢迎调剂
+1/10
-
南昌航空大学 材料学院 招材料类调剂研究生，名额多，上岸机会大
+1/8
-
【2026考研调剂】浙江万里学院国家级青年人才团队-锂电/电催化方向招收调剂生
+1/5
-
江西水利电力大学市政工程接受调剂
+1/4
-
重庆工商大学 教育部研究中心招收化工/环境/材料/石油/化机方向2026年调剂研究生
+1/4
-
青岛大学硕士调剂（物理/材料，计算模拟方向，欢迎联系）
+1/3
-
上海应用技术大学化工学部招生调剂
+1/3
-
北京农学院植物保护招收1名学硕
+1/3
-
韩国汉阳大学首尔校区ADIP实验室诚招博士后
+1/2
★
药渡(金币+1): 谢谢参与
药渡(金币+1): 谢谢参与
|
本帖内容被屏蔽 |
14楼2015-11-20 16:01:12
简单回复
sxln2楼
2015-11-20 15:48
回复
药渡(金币+1): 谢谢参与
laom20133楼
2015-11-20 15:50
回复
药渡(金币+1): 谢谢参与
2015-11-20 15:50
回复
药渡(金币+1): 谢谢参与
2015-11-20 15:50
回复
药渡(金币+1): 谢谢参与
。 发自小木虫Android客户端
天涯20126楼
2015-11-20 15:51
回复
药渡(金币+1): 谢谢参与
skyish7楼
2015-11-20 15:52
回复
药渡(金币+1): 谢谢参与
2015-11-20 15:54
回复
药渡(金币+1): 谢谢参与
dmbb9楼
2015-11-20 15:57
回复
药渡(金币+1): 谢谢参与
江南的竹10楼
2015-11-20 15:58
回复
药渡(金币+1): 谢谢参与
。 [ 发自小木虫客户端 ]
chenchenyf11楼
2015-11-20 15:59
回复
药渡(金币+1): 谢谢参与
xiejiaf12楼
2015-11-20 16:00
回复
药渡(金币+1): 谢谢参与
feiyief13楼
2015-11-20 16:01
回复
药渡(金币+1): 谢谢参与
mhycpxir15楼
2015-11-20 16:01
回复
药渡(金币+1): 谢谢参与
irshvj16楼
2015-11-20 16:02
回复
药渡(金币+1): 谢谢参与
kolimm17楼
2015-11-20 16:02
回复
药渡(金币+1): 谢谢参与
祝福
am435918楼
2015-11-20 16:02
回复
药渡(金币+1): 谢谢参与
wblxcs19楼
2015-11-20 16:02
回复
药渡(金币+1): 谢谢参与
祝福
wnotffisg20楼
2015-11-20 16:03
回复
药渡(金币+1): 谢谢参与
祝福
ahsjlyu21楼
2015-11-20 16:03
回复
药渡(金币+1): 谢谢参与
.
keoxri22楼
2015-11-20 16:03
回复
药渡(金币+1): 谢谢参与
vrxcyvkss23楼
2015-11-20 16:03
回复
药渡(金币+1): 谢谢参与
,
ooxmfc24楼
2015-11-20 16:04
回复
药渡(金币+1): 谢谢参与
ucmxjl25楼
2015-11-20 16:04
回复
药渡(金币+1): 谢谢参与
,
bincmq26楼
2015-11-20 16:04
回复
药渡(金币+1): 谢谢参与
祝福
fqmkia27楼
2015-11-20 16:04
回复
药渡(金币+1): 谢谢参与
wxubpn28楼
2015-11-20 16:05
回复
药渡(金币+1): 谢谢参与
祝福
iygbojqj29楼
2015-11-20 16:05
回复
药渡(金币+1): 谢谢参与
sjtdeud30楼
2015-11-20 16:05
回复
药渡(金币+1): 谢谢参与
shsvoy31楼
2015-11-20 16:05
回复
药渡(金币+1): 谢谢参与
cmyfna32楼
2015-11-20 16:06
回复
药渡(金币+1): 谢谢参与
sgadsdkc33楼
2015-11-20 16:06
回复
药渡(金币+1): 谢谢参与
,
quainyni34楼
2015-11-20 16:06
回复
药渡(金币+1): 谢谢参与
wbwwrs35楼
2015-11-20 16:06
回复
药渡(金币+1): 谢谢参与
祝福
yuduoj36楼
2015-11-20 16:06
回复
药渡(金币+1): 谢谢参与
支持
ofresq37楼
2015-11-20 16:06
回复
药渡(金币+1): 谢谢参与
.
tanmingp38楼
2015-11-20 16:06
回复
药渡(金币+1): 谢谢参与
qdjoupudwqx39楼
2015-11-20 16:06
回复
药渡(金币+1): 谢谢参与
,
qyoycw40楼
2015-11-20 16:07
回复
药渡(金币+1): 谢谢参与
fangfengw41楼
2015-11-20 16:07
回复
药渡(金币+1): 谢谢参与
祝福
virologik42楼
2015-11-20 16:07
回复
药渡(金币+1): 谢谢参与
liufeic43楼
2015-11-20 16:07
回复
药渡(金币+1): 谢谢参与
xiachaz44楼
2015-11-20 16:07
回复
药渡(金币+1): 谢谢参与
hodydo45楼
2015-11-20 16:07
回复
药渡(金币+1): 谢谢参与
zhangfangp46楼
2015-11-20 16:07
回复
药渡(金币+1): 谢谢参与
hudouz47楼
2015-11-20 16:07
回复
药渡(金币+1): 谢谢参与
祝福
ffwmeg48楼
2015-11-20 16:07
回复
药渡(金币+1): 谢谢参与
.
yushat49楼
2015-11-20 16:07
回复
药渡(金币+1): 谢谢参与
qiyingy50楼
2015-11-20 16:07
回复
药渡(金币+1): 谢谢参与
支持
